Get notified when IMVT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Hanall Dispute Risk (new) — Company notified HanAll of batoclimab discontinuation; HanAll may disagree with the decision, potentially leading to arbitration or litigation over the licensing agreement.
IMVT: net income -$153.2M. Immunovant discontinues batoclimab after Phase 3 failures, narrows focus to IMVT-1402
Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~2 min read
Key Changes
-
high
Batoclimab discontinued in April 2026 after two Phase 3 TED trials failed to meet primary endpoints; company now focuses exclusively on IMVT-1402, eliminating one of two lead programs.
MD&A: batoclimab discontinuation verify on EDGAR → -
high
IMVT-1402 showed 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 response rates in difficult-to-treat rheumatoid arthritis at Week 16—first patient efficacy data for the asset.
MD&A: IMVT-1402 D2T RA efficacy data verify on EDGAR → -
high
Net loss widened 27.0% to $153.2 million in Q1 FY2027 as R&D spending rose $41.4 million year-over-year, driven by accelerated IMVT-1402 trials and batoclimab wind-down costs.
MD&A: quarterly net loss verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.
Partner
Trade IMVT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 26, 2026 · How we verify